JAMA Neurology Data Shows Meaningful Effects With Biogen's QALSODY In Long-Term Results

JAMA Neurology published final results from Biogen's Phase 3 VALOR study and its open-label extension evaluating QALSODY (tofersen) for SOD1-ALS with an average follow-up of 4.9 years (range 3.6–5.4); VALOR enrolled 108 patients (72 on tofersen, 36 placebo) and 95 entered the OLE. Approximately 27% of participants in the early-start group experienced improvements in muscle strength over about three years; QALSODY received accelerated U.S. approval in April 2023 based on reduced plasma neurofilament light chain, with continued approval contingent on confirmatory trials. Biogen is also running the presymptomatic ATLAS study; Biogen shares have traded in a $110.04–$185.17 range over the year and closed at $174.70 (down 0.06%).

Analysis

Market structure: Biogen is the direct beneficiary — an approved, differentiated ASO (tofersen/QALSODY) with 27% early-start muscle-strength improvement over ~3 years creates a high-margin but very small addressable US market (~330 SOD1-ALS patients; SOD1 ~2% of ALS). Commercial upside is capped absent label expansion (presymptomatic ATLAS) — using conservative pricing scenarios of $200k–$1M per patient yields US peak sales roughly $66M–$330M at full penetration, so valuation upside is more binary/catalyst-driven than volume-driven.

Risk assessment: Key tail risks are regulatory reversals or negative confirmatory readouts that would remove accelerated approval (binary downside >30–50% historically for similar events) and payer restrictions (CMS/NCD or private step-editing) that can limit uptake to monitored biomarker populations. Near-term (days–weeks): limited market moves; short-term (3–12 months): payer guidance and ATLAS enrolment/biomarker milestones; long-term (12–36 months): confirmatory outcomes and real-world safety/efficacy shape valuation.

Trade implications: Favor idiosyncratic, hedged exposure to BIIB rather than large outright biotech long. Options strategies (12-month in-the-money call spreads financed by selling OTM calls or buying protective 30% OTM puts) extract asymmetric upside around ATLAS/confirmatory catalysts while capping downside. Rotate modest capital from speculative rare-disease small-caps into ASO-platform names (e.g., Ionis) and Biogen to capture platform optionality.

Contrarian angles: Consensus may overweight headline efficacy and underweight commercial/pricing constraints and Aduhelm-like reimbursement risks — market may underprice downside from confirmatory failure. Historical parallels: accelerated approvals (Aduhelm, eteplirsen) show large post-approval drawdowns after payer pushback; therefore volatility will persist and creates targeted arbitrage opportunities for disciplined hedged positions.

Key Decisions for Investors

• Establish a staged 2–3% long position in BIIB over 4 weeks (scale-in 25% weekly) to target catalyst upside (ATLAS enrollment, confirmatory data over 12–36 months); immediately hedge with a 12-month 30% OTM protective put sized to cover 50% of position notional to limit binary downside.
• Implement a directional options trade instead of outright stock: buy a 12-month BIIB ATM call and sell a 12-month call 35–40% OTM (call spread) sized to 1–1.5% portfolio risk; this captures upside if confirmatory/ATLAS news is positive while capping premium paid.
• Pair trade: go long BIIB (1% portfolio) and short the iShares Biotechnology ETF (IBB) equal notional (0.75%) to isolate Biogen-specific approval/launch upside versus sector moves; rebalance after each headline within 2–6 weeks.
• Reduce exposure to speculative rare-disease microcaps by 25% and redeploy 0.5–1% into Ionis Pharmaceuticals (IONS) over 6–18 months to gain ASO platform exposure; monitor CMS/NCD guidance and ATLAS biomarker thresholds (plasma NfL elevation) over the next 30–90 days as sell/buy triggers.